Lexicon Pharmaceuticals Inc (LXRX): Not A Time To Panic Nor Freeze

Lexicon Pharmaceuticals Inc (LXRX) concluded trading on Wednesday at a closing price of $2.04, with 4.38 million shares of worth about $8.94 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 100.00% during that period and on April 3, 2024 the price saw a loss of about -7.69%. Currently the company’s common shares owned by public are about 244.92M shares, out of which, 239.51M shares are available for trading.

However, the stock later moved at a day high price of 2.2392, or with a loss of -7.69%. Stock saw a price change of 3.03% in past 5 days and over the past one month there was a price change of -7.69%. Year-to-date (YTD), LXRX shares are showing a performance of 33.33% which decreased to -16.05% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.92 but also hit the highest price of $3.79 during that period. The average intraday trading volume for Lexicon Pharmaceuticals Inc shares is 4.81 million. The stock is currently trading -13.01% below its 20-day simple moving average (SMA20), while that difference is down -12.69% for SMA50 and it goes to 17.81% higher than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Lexicon Pharmaceuticals Inc (NASDAQ: LXRX) currently have 244.92M outstanding shares and institutions hold larger chunk of about 73.93% of that.

The stock has a current market capitalization of $502.33M and its 3Y-monthly beta is at 1.29. It has posted earnings per share of -$0.79 in the same period. It has Quick Ratio of 5.58 while making debt-to-equity ratio of 1.14. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LXRX, volatility over the week remained 10.65% while standing at 9.30% over the month.

Analysts are in expectations that Lexicon Pharmaceuticals Inc (LXRX) stock would likely to be making an EPS of -$0.2 in the current quarter, while forecast for next quarter EPS is -$0.18 and it is -$0.66 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.2 which is -$0.19 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.17 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 10.13% while it is estimated to increase by 7.51% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on March 07, 2023 offering a Hold rating for the stock and assigned a target price of $3 to it. Coverage by Piper Sandler stated Lexicon Pharmaceuticals Inc (LXRX) stock as an Overweight in their note to investors on August 12, 2022, suggesting a price target of $10 for the stock. On January 29, 2021, JP Morgan Upgrade their recommendations, while on January 29, 2021, Wedbush Downgrade their ratings for the stock with a price target of $8. Stock get a Buy rating from Citigroup on December 08, 2020.

Most Popular

Related Posts